No influence of CYP3A43 rs472660G>A on steady-state serum olanzapine concentrations in White psychiatric patients

2014 ◽  
pp. 1
Author(s):  
Mao M. Söderberg ◽  
Espen Molden ◽  
Marja-Liisa Dahl
Keyword(s):  
Steady State ◽  
Psychiatric Patients ◽  
Steady State Serum

Plasma Concentration Monitoring of Hydroxylated Metabolites of Imipramine and Desipramine

1981 ◽  
Vol 15 (4) ◽  
pp. 263-266 ◽  
Author(s):  
C. Lindsay DeVane ◽  
William J. Jusko
Keyword(s):  
Steady State ◽  
Psychiatric Patients ◽  
Similar Group ◽  
Serum Concentrations ◽  
Considerable Variability ◽  
Hydroxylated Metabolites ◽  
Metabolite Concentrations ◽  
Steady State Serum ◽  
Antidepressant Efficacy ◽  
Hydroxy Metabolite

Steady-state serum concentrations of imipramine (IMI), its demethylated metabolite desipramine (DMI), and the active, hydroxylated metabolites, 2-hydroxy-imipramine (2-OH-IMI) and 2-hydroxy-desipramine (2-OH-DMI) were monitored in 126 psychiatric patients receiving IMI therapy. DMI and 2-OH-DMI concentrations were determined in a similar group of 61 DMI-treated patients. Although significant correlations exist between hydroxy metabolite and precursor concentrations, considerable variability was also found. Mean (± SD) ratios for the IMI patients were: 2-OH-IMI:IMI = 0.27 (± 0.19) and 2-OH-DMI:DMI = 0.56 (± 0.30). The ratio of DMI: IMI for males and 2-OH-DMI:DMI for females decreased with age (r = −0.42 and −0.32, respectively, p < 0.01). Variable metabolite concentrations and the uncertainty of their relative psychoactivity may contribute to the difficulties in relating antidepressant efficacy to serum concentrations of the administered IMI or DMI.

Effect of naproxen on the steady-state serum concentration and anticoagulant activity of warfarin

1979 ◽  
Vol 25 (1) ◽  
pp. 61-66 ◽  
Author(s):  
Adesh Jain ◽  
F. Gilbert McMahon ◽  
John T. Slattery ◽  
Gerhard Levy
Keyword(s):  
Steady State ◽  
Serum Concentration ◽  
Anticoagulant Activity ◽  
Steady State Serum

scholarly journals Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin

2021 ◽  
Author(s):  
Zhaoyang Li ◽  
Barbara McCoy ◽  
Werner Engl ◽  
Leman Yel
Keyword(s):  
Steady State ◽  
Trough Level ◽  
Geometric Mean ◽  
Time Profiles ◽  
Level Measurement ◽  
Serum Igg ◽  
Pharmacokinetic Assessment ◽  
Steady State Serum ◽  
Serum Igg Levels ◽  
Trough Levels

AbstractPatients with primary immunodeficiency diseases often require lifelong immunoglobulin (IG) therapy. Most clinical trials investigating IG therapies characterize serum immunoglobulin G (IgG) pharmacokinetic (PK) profiles by serially assessing serum IgG levels. This retrospective analysis evaluated whether steady-state serum IgG trough level measurement alone is adequate for PK assessment. Based on individual patient serum IgG trough levels from two pivotal trials (phase 2/3 European [NCT01412385] and North American [NCT01218438]) of weekly 20% subcutaneous IG (SCIG; Cuvitru, Ig20Gly), trough level-predicted IgG AUC (AUCτ,tp) were calculated and compared with the reported AUC calculated from serum IgG concentration-time profiles (AUCτ). In both studies, mean AUCτ,tp values for Ig20Gly were essentially equivalent to AUCτ with point estimates of geometric mean ratio (GMR) of AUCτ,tp/AUCτ near 1.0 and 90% CIs within 0.80–1.25. In contrast, for IVIG, 10%, mean AUCτ,tp values were lower than AUCτ by >20%, (GMR [90% CI]: 0.74 [0.70–0.78] and 0.77 [0.73–0.81] for the two studies, respectively). Mean AUCτ,tp values calculated for 4 other SCIG products (based on mean IgG trough levels reported in the literature/labels) were also essentially equivalent to the reported AUCτ (differences <10% for all except HyQvia, a facilitated SCIG product), while differences for IVIG products were >20%. In conclusion, steady-state serum IgG levels following weekly SCIG remain stable, allowing for reliable prediction of AUC over the dosing interval using trough IgG levels. These findings indicate that measuring steady-state serum IgG trough levels alone may be adequate for PK assessment of weekly SCIG.

Relationship of steady-state serum concentrations of amiodarone and desethylamiodarone to therapeutic efficacy and adverse effects

1987 ◽  
Vol 82 (6) ◽  
pp. 1102-1108 ◽  
Author(s):  
Ruth Falik ◽  
Belinda T. Flores ◽  
Leslie Shaw ◽  
Gene A. Gibson ◽  
Mark E. Josephson ◽  
...  
Keyword(s):  
Steady State ◽  
Adverse Effects ◽  
Therapeutic Efficacy ◽  
Serum Concentrations ◽  
Steady State Serum ◽  
Relationship Of

Cimetidine's Effect on Steady-State Serum Nortriptyline Concentrations

1983 ◽  
Vol 17 (12) ◽  
pp. 904-905 ◽  
Author(s):  
Del D. Miller ◽  
John B. Sawyer ◽  
J. Patrick Duffy
Keyword(s):  
Steady State ◽  
Black Male ◽  
Concomitant Administration ◽  
Steady State Serum ◽  
Clinical Consequences

A cimetidine-nortriptyline interaction in a 52-year-old black male is reported. After concomitant administration of cimetidine and nortriptyline for two weeks, steady-state nortriptyline concentrations fell 42 percent when cimetidine was discontinued. Later, during rechallenge with cimetidine, serum nortriptyline concentrations increased significantly, but subsequently fell again when cimetidine was discontinued. The possible clinical consequences of this interaction are discussed.

Carbamazepine-Isoniazid Interaction

PEDIATRICS ◽  
1983 ◽  
Vol 71 (1) ◽  
pp. 139-139
Author(s):  
J. M. WRIGHT
Keyword(s):  
Case Report ◽  
Steady State ◽  
Significant Interaction ◽  
Similar Case ◽  
Drug Regimen ◽  
Acetylator Phenotype ◽  
Serum Concentrations ◽  
Slow Acetylator ◽  
Steady State Serum ◽  
Clinically Significant

To the Editor.— The case report of carbamazepine intoxication secondary to isoniazid administration recently described in this journal1 is a clinically significant interaction. I have previously presented2 a similar case in which a patient receiving carbamazepine, valproate, and nitrazepam developed severe carbamazepine intoxication when isoniazid was added to the drug regimen. The patient was determined to have inherited the slow acetylator phenotype. On careful rechallenge, 300 mg of isoniazid increased carbamazepine steady-state serum concentrations by 85% and decreased carbamazepine clearance by 45%.

Sign in / Sign up

Export Citation Format

Share Document